Science at KOMO
KOMO Biosciences is building a new foundation for genome engineering through non-viral, targeted DNA insertion. Our platforms enable the precise integration of large genetic payloads into defined genomic locations, giving developers greater control over where, how, and what is added to the genome.
Rather than focusing on modifying existing genes, KOMO focuses on gene addition. This shift makes it possible to design and deploy more sophisticated biological systems, from engineered immune cells to complex biologics and agricultural traits, with greater predictability and scalability.
A Different Approach to Genome Engineering
Many genome engineering technologies rely on viral delivery or cellular DNA repair pathways to introduce new genetic material. While powerful, these approaches can introduce variability, limit payload size, and complicate manufacturing and translation.
KOMO takes a different approach by using site specific integrase mediated DNA insertion. Our platforms enable direct integration of large DNA sequences without relying on unprotected double strand DNA breaks or error prone repair mechanisms. The result is a more controlled, predictable, and scalable way to engineer genomes.
This approach is designed to support applications where precision and consistency matter most, including:
- advanced cell and gene therapy enablement
- biologics development and biomanufacturing
- engineered cell systems
- agricultural biotechnology
Built for the Next Wave of Biology
As the life sciences move toward increasingly complex genetic designs, the ability to reliably insert large and multi gene constructs becomes critical. KOMO’s platforms are designed to meet this need by enabling:
- non-viral delivery compatible genome engineering
- targeted integration into defined genomic locations
- support for large and complex DNA payloads
- predictable genomic outcomes at scale
KOMO does not develop therapeutics internally. Instead, we provide the genome engineering infrastructure that partners use to build the next generation of therapies, biologics, and engineered cell systems.